Optimized Heparin Regimen in Vascular Surgery

Peripheral Revascularisation Clinical Trial

Official title:

A Pilot Study on the Influence of an Optimized Heparin Regimen on the Hemostatic Environment Downstream From the Surgical Clamp in Major Vascular Surgery.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02477072
• Other study ID #: 15.077
• Status: Completed
• Phase: N/A
• First received: June 16, 2015
• Last updated: January 11, 2016
• Start date: September 2015
• Est. completion date: January 2016

Study information

• Verified date: January 2016
• Source: Centre hospitalier de l'Université de Montréal (CHUM)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Interventional

Clinical Trial Summary

Hypothesis: Optimal anticoagulation defined as an Activated Clotting Time (ACT) of 300 to 350 seconds obtained by weight-adjusted doses of unfractionated heparin (UFH) will improve the hemostatic environment downstream from the vascular clamp, provide better blood flow in the distal bed following peripheral revascularization surgery.

Objectives: This study is designed to assess the effects of an optimized regimen of UFH on the hemostatic environment downstream from the vascular clamp in major vascular surgery.

Description:

Peripheral revascularization surgery is usually performed in high-risk patients, suffering from major comorbidities. Complications associated with vascular surgery include coronary problems, arrhythmias, failure of revascularization and thrombosis. In order to prevent these complications and possible re-interventions it is essential to optimize the intraoperative path.

Unfractionated heparin is commonly used during arterial vascular surgery to prevent thrombosis and accumulation of thrombi at the surgical site. UFH is administered before clamping and blood flow interruption. However, the best heparin regimen to achieve optimal anticoagulation for peripheral revascularization remains unknown, with current recommendations based on data from the coronary literature and guidelines. Few studies have assessed the effect of vascular clamping and blood flow interruption on the anticoagulation in the distal vascular bed.

Perioperative monitoring of coagulation is important to diagnose potential causes of hemorrhage and guide hemostatic therapies. Routine laboratory-based coagulation tests such as prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) and platelet count are used to assess the patient's coagulation status. However, the value of these tests has been questioned in the acute perioperative setting for the following reasons: substantial delays between blood sampling and results, tests performed on plasma rather than whole blood and lack of information on platelet function.

The activated clotting time (ACT) is used to monitor anticoagulation and, indirectly, concentrations of UFH. The ACT is measured on whole blood in cuvettes containing high concentrations of activators, typically celite or kaolin. Modern methods are completely automated. ACT measurement with point-of-care devices is used during procedures requiring anticoagulation, such as cardiopulmonary bypass, interventional cardiology and hemodialysis. In vascular surgery, the target ACT is not clearly defined and therefore not systematically monitored.

Thromboelastography (TEG) is a bedside coagulation test that enables evaluation of all components of hemostasis. An advantage of TEG over conventional tests of hemostasis is that it is performed on whole blood, taking into consideration the role of interacting blood elements. The TEG can also be adapted to different clinical situations. Activators such as tissue factor, celite and thrombin can be added to whole blood to accelerate the analysis. TEG cups coated with heparinase can also be used to degrade heparin without affecting other coagulation parameters.

Ankle-brachial (ABI) and toe-brachial (TBI) indexes are currently used to evaluate patients with peripheral arterial disease. These non-invasive tests provide information about peripheral blood flow. The ankle-brachial index is the ratio of the systolic blood pressure at the ankle to that measured at the brachial artery. The diagnostic limits of the ABI have been confirmed in several large-scale studies. Conditions associated with medial calcifications, such as diabetes, chronic kidney disease or advanced age, can lead to false results due to vessel stiffness. The toe vessels are less susceptible to vessel stiffness, which makes the TBI useful.

Methods:

Monitoring and postoperative analgesia will be left to the discretion of the attending anesthesiologist. Surgery will be performed under general or regional anesthesia. For safety reasons, patients under regional anesthesia will automatically be assigned to receive a fixed dose of heparin.

UFH will be administered 2 minutes prior to vascular clamping according to randomization. Blood samples will be collected at the following time points for ACT and TEG analysis: following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room. Heparin will be neutralized with protamine if needed.

Intraoperative blood losses will be recorded. Administration of crystalloids, colloids and blood products during surgery will be noted. Blood samples to assess cardiac troponin levels will be collected in the recovery room and on the day following surgery. Ankle-brachial and toe-brachial indexes will be measured preoperatively and postoperatively in the recovery room. The occurrence of cardiovascular complications will be noted during the hospital stay. The incidence of vascular re-interventions will be noted 30 days following surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: January 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients undergoing elective revascularization surgery

• American Society of Anesthesiologists (ASA) physical status l-lll inclusive

Exclusion Criteria:

• Known or suspected allergy to heparin or protamine

• Contraindication to heparin or protamine

• Known or suspected coagulopathy

• Current anticoagulation or residual effect of anticoagulants, antiplatelet agents, except aspirin

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Peripheral Revascularisation

Intervention

Procedure:
• ACT
Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
• TEG
Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
• Ankle-brachial index
Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
• Toe-brachial index
Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.

Drug:
• Heparin
Heparin doses will be administered according to the assigned group.

Locations

Country	Name	City	State
Canada	Centre Hospitalier de l'Université de Montréal (CHUM-Hôtel-Dieu)	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anticoagulation upstream and downstream from the clamp	Adequacy of anticoagulation upstream and downstream from the clamp will be assessed with the ACT and the thromboelastogram.	From induction of anesthesia until 30 minutes following the return of normal blood flow	Yes
Secondary	Peripheral blood flow	Peripheral blood flow will be assessed by the toe-brachial and ankle-brachial indexes	Before surgery and following surgery in the recovery room - on Day 1	Yes
Secondary	Occurence of any new revascularization surgery as a measure of safety and efficacy		From surgery until thirty days following surgery	Yes
Secondary	Occurrence of arrhythmia as a measure of safety		From surgery until discharge from the hospital - approximately 4 days	Yes
Secondary	Quantity of blood lost during surgery as a measure of safety		At the end of surgery - on Day 1	Yes
Secondary	Number of red blood cells transfusions administered as a measure of safety		From surgery until discharge from the hospital - approximately 4 days	Yes
Secondary	Occurence of thrombosis as a measure of safety		From surgery until discharge from the hospital - approximately 4 days	Yes